Novo Nordisk Q3 beats estimates on Wegovy pill growth and raises outlook
FROM THE WIRE · FINANCE.YAHOO.COM
Novo NVO reported adjusted third-quarter 2026 earnings of 89 cents per American Depositary Receipt (ADR), beating the Zacks Consensus Estimate of 81 cents. Adjusted earnings declined 12% year over year in Danish kroner from $1.03 per ADR in the prior-year quarter. Revenues of…
Read at the source ↗MARKET IMPACTHIGH✦ News Impact agent estimateTone: expected bullishA large pharma leader raising guidance on Wegovy pill growth can move the pharmaceutical sector.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Adjusted third-quarter 2026 earnings were 89 cents per ADR, beating the 81-cent estimate.
- 02Revenues of $12.19 billion surpassed the consensus estimate of $11.39 billion.
- 03The Wegovy pill generated DKK 5.39 billion in sales.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets